684 related articles for article (PubMed ID: 29882203)
1. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
Al-Gareeb AIA; Gorial FI; Mahmood AS
Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
[TBL] [Abstract][Full Text] [Related]
2. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
3. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
4. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
5. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
6. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
Matsuno H; Tomomitsu M; Hagino A; Shin S; Lee J; Song YW
Ann Rheum Dis; 2018 Apr; 77(4):488-494. PubMed ID: 29259050
[TBL] [Abstract][Full Text] [Related]
7. Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis.
Takeuchi T; Miyasaka N; Pedersen R; Sugiyama N; Hirose T
Mod Rheumatol; 2020 Mar; 30(2):259-268. PubMed ID: 30836801
[No Abstract] [Full Text] [Related]
8. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
9. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
Kameda H; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Takeuchi T;
Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study.
Yamanaka H; Nagaoka S; Lee SK; Bae SC; Kasama T; Kobayashi H; Nishioka Y; Ueki Y; Seto Y; Nishinarita M; Tamura N; Kimura N; Saito K; Tomita T; Nawata Y; Suzuki S; Ishigatsubo Y; Munakata Y; Makino Y; Inoue E; Tanaka Y; Takeuchi T;
Mod Rheumatol; 2016 Sep; 26(5):651-61. PubMed ID: 26698929
[TBL] [Abstract][Full Text] [Related]
11. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW
Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455
[TBL] [Abstract][Full Text] [Related]
13. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y;
Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864
[TBL] [Abstract][Full Text] [Related]
14. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.
Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A
Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609
[TBL] [Abstract][Full Text] [Related]
15. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Koyama Y; Shiraishi H; Ohta T; Uchino A
Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
[TBL] [Abstract][Full Text] [Related]
16. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
17. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
Shi ZC; Fei HP; Wang ZL
Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
[TBL] [Abstract][Full Text] [Related]
19. [Etanercept combined with Tripterygium wilfordii polyglycoside for treatment of rheumatoid arthritis in the elderly: a clinical study].
He WZ; Yin ZH; Gao JH; Ye ZZ; Xie Y; Kong WH; Chen YS
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Mar; 34(3):267-71. PubMed ID: 24758073
[TBL] [Abstract][Full Text] [Related]
20. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
Zhang B; Jiang W
Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
